Press Release

World COPD Day 2017 on November 15th

The global prevalence of COPD is increasing at an alarming rate

AIRNERGY offers a promising therapy with Spirovitalisation

Hennef, Germany, November 14th 2017 — To quote Dr. Jorge Alberto Duque Media, Columbia, an authority on treatment of COPD (Chronic Obstructive Pulmonary Disease), "This illness is likely to become killer number one within the next four years!". The World Health Organisation (WHO) also predicts a similarly bleak development of the disease which, according to experts, already effects more than half a billion people worldwide of which approximately seven million live in Germany. Today, COPD is ranked the third most frequent cause of death and classified as a global problem. Even more alarming is that of the 10 most prevalent deadly illnesses, COPD is the only one with continually rising numbers.

Fifteen years ago, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) responded to this dramatic situation by initiating a World COPD Day which is an annual event held on the second or third Wednesday in November — this year it is held on November 15th. Conform with the previous years, the occasion is used to bring global attention to the illness, its progression and therapies.

COPD defines a group of lung diseases. Primarily, chronic obstructive bronchitis and pulmonary emphysema. Both illnesses are characterised by obstruction during exhalation. The most common cause of COPD is smoking (including passive smoking) and the related damage to lung tissue; it has been proven that 80 to 90 percent of all COPD patients either smoke or have smoked in the past. Other causes include prolonged durations of stay in

polluted environments — caused by smoke, dust or gas —, asthma, pulmonary infections as a child and other inadequately treated respiratory illnesses.

Part of treating COPD is to stop the cause, i.e., to refrain from smoking and to stay away from dust. Expectorants and anti-inflammatory medication, as well as those that dilate the bronchi, help the patient to breathe more freely. Long-term oxygen therapies and other complementary procedures such as acupuncture, breathing exercises and homeopathy are also practiced.

Airnergy, a medical device manufacturer based in Hennef, Germany, has devoted itself to creating a new and promising therapy for this widespread disease. Many of the prescribed COPD medications have a direct impact on the vegetative nervous system causing irritation of various organs which, long-term, results in a worsening of the symptoms. They stimulate the sympathetic nervous system, tense nerves, which activates the fight and flight system and creates additional stress for COPD patients who are already under considerable psychological duress. Further, they inhibit the parasympathetic nervous system, relax nerves, which is responsible for recuperation, repair and regeneration. Consequently, they suppress the body's own repair processes which is made apparent through symptoms such as fever, inflammation and exhaustion.

Airnergy's Spirovital therapy, which has won the company international acclaim and many awards, opens up completely new perspectives for COPD patients: improved energy intake via the lung without increased medication or oxygen supplementation.

The relevance of air as a "nutrient" should not be underestimated. Every day, a human being inhales and exhales approximately 21 000 times, which equates to around 7.5 million breaths per year — and more than half a billion breaths during the span of a lifetime. However, roughly 75% of the inhaled oxygen is exhaled unused. Airnergy has developed a method by which the ambient oxygen (21%) can be prepared naturally (similar to photosynthesis in

green leaves) so that the human organism is capable of converting it to energy more efficiently. By using this innovative health system, energy rich air can be absorbed via the lungs where it can be utilised directly within the cells as well as intracellularly. At the same time, the energy is transported by hydrogen bonds within the vascular system which in turn positively influences the metabolism.

COPD patients should inhale energised air one to two times per day for 21 minutes over a period of at least six months. This is effected via a lightweight nasal cannula. "Our spirovitalisation technology activates and supports the body's own self-healing processes. Contrary to more common oxygen therapies, the body is neither subjected to increased levels of oxygen nor ionisation thereof. The treatment is also free of ozone and other foreign chemical substances of any kind," explains Guido Bierther, Airnergy founder and managing director.

Dr. Jorge Alberto Duque Mejia has worked incessantly to find a successful form of COPD therapy. This includes Spirovital therapy which he has used to help thousands of patients in his practice. He is enthused by the Airnergy method: "The four-catalyst unit is ideally suited to treat COPD: Without exception, all my patients have demonstrated a considerable improvement in their lung function and their overall well-being. If my sister, who died as a result of COPD, had been able to use the Airnergy unit, I am sure she would still be alive today. My objective is to make as many COPD patients aware of the benefits of spirovitalisation as I possibly can."

The picture shows Nicole Renneberg from the Gesundheitslounge talking to Rainer Patt, a Taxi business owner in Eitorf/Sieg, Germany, as he explains the benefits of regularly partaking in Airnergy spirovitalisation at "Bio-Bärbel" — the country's first Bio-Bistro in Eitorf.

Further information concerning Airnergy can be found at www.airnergy.com and visit www.gesundheitslounge.de to explore Gesundheitslounge including tips on health, happiness and stress reduction.

Michael Nassenstein, tel. +49 163 34 19 03 9, mna — 2017-1102

Contact at AIRNERGY:

Guido Bierther

Tel.: +49 (0)2202 93 30 0 Fax: +49 (0)2202 93 30 30

E-mail: <u>g.bierther@airnergy.com</u>